Registered Nurse in Pacific Grove, CA Accepting Medicare
4 Registered Nurse nurses found. Showing 1 - 4
 Mrs. Katrina Powley, RN, BSN, CSN Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 435 Hillcrest Ave, Pacific Grove, CA 93950 Phone: 831-275-5396 Fax: 831-607-8198 |
Mrs. Sonja Elizabeth Massey, R.N., I.B.C.L.C. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 529 Central Ave, Suite 205, Pacific Grove, CA 93950 Phone: 831-402-1666 Fax: 831-657-9702 |
Ms. Patricia Skinner Williams, RN, IBCLC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 529 Central Ave, Pacific Grove, CA 93950 Phone: 831-917-6387 Fax: 831-657-9702 |
Trina Ammar, RN, IBCLC Registered Nurse - Lactation Consultant Medicare: Not Enrolled in Medicare Practice Location: 1120 Forest Ave # 181, Pacific Grove, CA 93950 Phone: 831-229-1114 |
News Archive
High Court hears arguments regarding access to docs' prescribing data
In this case, the state of Vermont is battling drug companies and data-mining firms. Vermont's law bans the sale of prescribing information unless physicians "opt in" and make their records available.
InhibOx and COSMIC discoveries align to deliver full service drug discovery offering
InhibOx Ltd (spin-out of Oxford, UK) and the COSMIC Discoveries (the independent service arm of the Institute of Life Sciences, Hyderabad, India) today announce that they have formed a close strategic partnership to deliver a full service drug discovery service offering, incorporating expert computational, medicinal and synthetic chemistry design capabilities. Both commercial organizations, linked to world-leading academic institutes, have built their services on advanced proprietary science and technology. Together, they offer unique capabilities that are able to address the most demanding drug discovery challenges on behalf of biotech and pharmaceutical companies worldwide.
Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today presented data that demonstrated patients treated for 10 and 15 years with COPAXONE® (glatiramer acetate injection) had significant reduction in disease severity. These data, generated from the longest continuous prospective study of any disease modifying therapy in relapsing remitting multiple sclerosis (RRMS), were presented today at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.
EMBL, five countries sign ELIXIR's Memorandum of Understanding
Today marks an important step for ELIXIR, Europe's emerging research infrastructure for life-science information, as five countries plus the European Molecular Biology Laboratory (EMBL) have signed a Memorandum of Understanding to catalyse the implementation and construction of ELIXIR.
› Verified 4 days ago